AUSTIN, Texas--(BUSINESS WIRE)--Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that the National Cancer Institute (NCI) has awarded the company a Phase I/Phase II “Fast-Track” Small Business Innovation Research (SBIR) Contract valued at $1,126,627. The contract will fund the development of 50 new quantitative, multiplexed immunoassays for cancer-related proteins to be added to the automated RBM Human Multi-Analyte Profile (HumanMAP®) platform. With the addition of these tests, RBM’s HumanMAP® will be expanded to more than 100 quantitative immunoassays for cancer biomarkers (as part of an existing panel of nearly 300 immunoassays) available for fast, sensitive, reproducible and cost-effective use by the worldwide community of cancer researchers.
